AU2021269585A1 - IL-2 fusion polypeptide compositions and methods of making and using the same - Google Patents

IL-2 fusion polypeptide compositions and methods of making and using the same Download PDF

Info

Publication number
AU2021269585A1
AU2021269585A1 AU2021269585A AU2021269585A AU2021269585A1 AU 2021269585 A1 AU2021269585 A1 AU 2021269585A1 AU 2021269585 A AU2021269585 A AU 2021269585A AU 2021269585 A AU2021269585 A AU 2021269585A AU 2021269585 A1 AU2021269585 A1 AU 2021269585A1
Authority
AU
Australia
Prior art keywords
composition
polypeptide
certain embodiments
aqueous solution
composition comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021269585A
Other languages
English (en)
Inventor
Francisca O. GBORMITTAH
Tarek A. Zeidan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mural Oncology Inc
Original Assignee
Mural Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mural Oncology Inc filed Critical Mural Oncology Inc
Publication of AU2021269585A1 publication Critical patent/AU2021269585A1/en
Assigned to MURAL ONCOLOGY, INC. reassignment MURAL ONCOLOGY, INC. Request for Assignment Assignors: ALKERMES PHARMA IRELAND LIMITED
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2021269585A 2020-05-11 2021-05-10 IL-2 fusion polypeptide compositions and methods of making and using the same Abandoned AU2021269585A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063022860P 2020-05-11 2020-05-11
US63/022,860 2020-05-11
PCT/US2021/031616 WO2021231319A1 (en) 2020-05-11 2021-05-10 Il-2 fusion polypeptide compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
AU2021269585A1 true AU2021269585A1 (en) 2022-12-15

Family

ID=78524880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021269585A Abandoned AU2021269585A1 (en) 2020-05-11 2021-05-10 IL-2 fusion polypeptide compositions and methods of making and using the same

Country Status (12)

Country Link
US (1) US20210395325A1 (https=)
EP (1) EP4149514A4 (https=)
JP (1) JP2023526024A (https=)
KR (1) KR20230008759A (https=)
CN (1) CN115867307A (https=)
AU (1) AU2021269585A1 (https=)
BR (1) BR112022022869A2 (https=)
CA (1) CA3172874A1 (https=)
IL (1) IL298064A (https=)
MX (1) MX2022014163A (https=)
TW (1) TW202207971A (https=)
WO (1) WO2021231319A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61391B1 (sr) * 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
EA202092926A3 (ru) * 2014-03-24 2021-10-29 Биовератив Терапьютикс Инк. Лиофилизированные составы, содержащие фактор ix
AU2015364396B2 (en) * 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
MX2019013142A (es) * 2017-05-05 2019-12-16 Amgen Inc Composicion farmaceutica que comprende construcciones de anticuerpos biespecificas para mejorar el almacenamiento y la administracion.
UA125971C2 (uk) * 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
MX2022004577A (es) * 2019-10-18 2022-05-10 Alkermes Pharma Ireland Ltd Agentes inmunomoduladores il-2 en combinacion con inhibidores de puntos de control inmune.

Also Published As

Publication number Publication date
EP4149514A1 (en) 2023-03-22
JP2023526024A (ja) 2023-06-20
MX2022014163A (es) 2023-02-22
BR112022022869A2 (pt) 2023-01-31
EP4149514A4 (en) 2024-06-26
US20210395325A1 (en) 2021-12-23
TW202207971A (zh) 2022-03-01
CA3172874A1 (en) 2021-11-18
CN115867307A (zh) 2023-03-28
KR20230008759A (ko) 2023-01-16
WO2021231319A1 (en) 2021-11-18
IL298064A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
US10639362B2 (en) Pharmaceutical compositions containing Clostridium difficile toxoids A and B
RU2413530C9 (ru) Стабильные препараты инсулинотропных пептидов
JP3065662B2 (ja) 副甲状腺ホルモン製剤
US11241498B2 (en) Room temperature stable lyophilized protein
JP6522711B2 (ja) Ｆｓｈの安定化
JP3702313B2 (ja) ゴナドトロピン含有薬剤組成物
KR102720834B1 (ko) Il-15 단백질 복합체 약학 조성물 및 이의 용도
BRPI0921429B1 (pt) Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
CA3156812A1 (en) Anti-connexin antibody formulations
KR20210113271A (ko) 콜라게나제 제형 및 이의 제조 방법
CN102670522B (zh) 含有重组人血清白蛋白-人粒细胞集落刺激因子融合蛋白的药物制剂及其制备
WO2022157806A1 (en) Freeze dried antibody formulations and methods thereof
JPH0314520A (ja) インターロイキン―１組成物
AU2021269585A1 (en) IL-2 fusion polypeptide compositions and methods of making and using the same
US20210371486A1 (en) Il-2 fusion polypeptide compositions and methods of making and using the same
AU2020304649B2 (en) Composition and methods for stabilizing liquid protein formulations
JP2005060377A (ja) インターロイキン−１１含有凍結乾燥製剤
WO2024023843A1 (en) A pharmaceutical formulation of a therapeuticantibody and preparations thereof
JP2024504462A (ja) Ｇｈｒｐ－６を含有する医薬組成物

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: MURAL ONCOLOGY, INC.

Free format text: FORMER APPLICANT(S): ALKERMES PHARMA IRELAND LIMITED

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period